PCI Effective as Surgery in Diabetes in Small Trial

BY MITCHEL L. ZOLER
Philadelphia Bureau

MUNICH — Patients with diabetes who received coronary stents fared just as well as similar patients who underwent coronary bypass surgery in a randomized study with 510 patients with 1 year of follow-up.

The results seemed to disprove the conventional wisdom that percutaneous coronary intervention (PCI) is not a good option for patients with diabetes because of their greater risk of restenosis, compared with nondiabetic patients, Dr. Anna L. Kastrati said at the annual congress of the European Society of Cardiology.

But some experts were skeptical of the finding, saying that a study with a total of 510 patients wasn’t large enough to definitively address the issue. “Five hundred patients is small for any comparison” of PCI and coronary surgery in patients with diabetes, commented Dr. Spencer B. King III, executive director of Academic Affairs at the Saint Joseph’s University of Philadelphia.

“Surgeons do patients like these”—patients who undergo stenting or have surgery, commented the study’s cochair, Dr. Friedrich W. Mohr, professor of interventional cardiology at the University of Leipzig, Germany.

“The 1-year follow-up is very short, the study was very underpowered, and the results are inconclusive,” commented Dr. Valentin Fuster, professor of medicine and director of the cardiovascular institute at Mount Sinai Hospital in New York. He also suggested waiting for the FREEDOM results.

The Coronary Artery Revascularization in Diabetes (CARDIA) trial was done at 24 hospitals in the United Kingdom and Ireland. It randomized patients with diabetes and either multivessel coronary disease or complex single- vessel disease who were suitable for either PCI or coronary bypass grafting (CABG).

When the study began in 2002, bare-metal stents were used but this changed once sirolimus-eluting coronary stents (Cypher) came on the market. The patients’ average age was 64 years, and about 31% were on insulin treatment. The study received support from Cordis, the company that markets Cypher stents, as well as many other device and drug companies. The study’s primary sponsor was Hammersmith Hospitals NHS Trust, London. Dr. Kapur said he had no relevant disclosures.

The study’s primary end point was the combined rate of death, nonfatal myocardial infarction, or nonfatal stroke after 1 year. The rate was 10.2% in 245 patients treated with CABG, and 11.6% in the 251 patients treated with PCI, a difference that was not statistically significant, reported Dr. Kapur, a cardiologist at the London Chest Hospital.

As in the other major comparison of PCI and CABG presented at the meeting, the SYNTAX study, the rate of stroke was significantly lower in patients treated with PCI (0.4%) than in patients treated with CABG (2.5%). On the other hand, the PCI patients had a higher rate of nonfatal MIs (8.4%), although not significantly higher than the CABG patients (5.7%). Also as in SYNTAX, the rate of repeat revascularization was significantly higher in the PCI patients (9.9%) than in the CABG patients (2.0%), but unlike SYNTAX, the CARDIA study did not include repeat revascularization in the primary end point.

When the analysis was confined to the 179 PCI patients who received a drug-eluting coronary stent (71% of the PCI patients), the results shifted a little more in favor of PCI. The rate of death, MI, or stroke in this PCI subgroup was 10.1%, including no strokes. The rate of repeat revascularization fell to 7.3%.

“There was always a fear that PCI did not perform well in patients with diabetes. What we’re impressed by is the improvement in both techniques,” PCI and CABG, said Dr. Kapur. “All the data suggest that drug-eluting stents have reduced the need for repeat revascularization in patients with diabetes. I have plenty of patients who do not want surgery and are prepared to have a second procedure” if they develop restenosis. “But other patients want it over and done with” and choose CABG, Dr. Kapur said.

Trade-Off: Stroke or Repeat PCI

SYNTAX from page 1

ease, 1,275 (41%) were judged by a team of cardiologists and cardiac surgeons to have no alternative in their revascularization treatment because of the complexity of their disease (including chronic total occlusion), comorbidity, or other factors that ruled out either surgery or stenting. For 1,077 of the nonrandomized patients (84%), bypass surgery was the only recourse; for the other 198 nonrandomized patients (16%), surgery was not feasible, so they were treated by PCI.

The other 1,800 patients (59%) in the study were deemed equally amenable to stenting or surgery and were randomized. In the results from both the randomized and registry arms highlighted recent progress toward better outcomes by both interventionalists and surgeons, the findings “probably will not change the number” of patients in routine practice who undergo stenting or have surgery, commented Dr. Spencer B. King III, an interventional cardiologist and executive director of academic affairs at Saint Joseph’s Health System in Atlanta.

Another limitation of the new findings is that patients were followed for just 1 year. The new data “add to the discussion of using PCI for left main disease, but 1 year of follow-up is not very long to say that survival in patients with left main disease” is as good as in patients treated with surgery, Dr. King said. “The danger is that patients who develop a severe restenosis in their left main may die.”

SYNTAX was done at 62 centers in Europe and 23 centers in the United States. Patients who entered the randomized part of the study had an average age of 65, and about 28% had diabetes. About two-thirds of patients had triple vessel disease, and about a third had a significant left main stenosis (patients with left main disease could also have additional stenoses in one, two, or three other coronary arteries). All of the lesions were previously untreated, none of the patients had an acute MI, and none of the bypass-surgery patients received concomitant cardiac surgery. The patients treated with stents received an average of 4.6 stents each. All of the coronary stents used in the study were paclitaxel-eluting models. Although the study used exclusively Taxus stents, Dr. Serruys and the study cochair, Dr. Friedrich W. Mohr, reported no conflicts of interest.

After 1 year, the combined rate of death, nonfatal cerebrovascular accident (stroke), or nonfatal MI was virtually identical: 7.6% in 903 PCI patients, compared with a 7.7% rate in the 897 patients treated with coronary artery bypass grafting (CABG).

The breakdown by individual event types showed that the only statistically significant difference between the two groups was a 2.2% rate of stroke in the CABG patients, compared with a 0.6% rate in the PCI patients. (See box.)

“The risk of death, stroke, and MI is identical between coronary stenting and surgery 1 year after intervention.”

The study’s primary end point combined the rate of these three “irreversible” events with the four major outcome, need for revascularization. The total for all four types of outcomes after 1 year was 12.1% in the CABG patients and 17.8% in the PCI patients, a statistically significant difference. This rate was also used to judge whether PCI was noninferior to CABG. The prespecified, noninferiority limit was a difference of less than 6.6% between the two treatments. Because the 95% confidence range for the quadruple end point was an excess as high as 8.3% in patients having PCI, the test for noninferiority was not met and so technically the results did not prove that PCI is not inferior to CABG.

But Dr. Serruys acknowledged that having a combined end point that included revascularization was a controversial decision. “We often talk about the hard, irreversible end points of death, stroke, and MI. The other four outcomes have the same value as the nuisance of going back for repeat revascularization,” said Dr. Serruys, professor of interventional cardiology at the thorax center at Erasmus University in Rotterdam, the Netherlands.

The 1-year rate of stent thrombosis or graft occlusion was also virtually identical, 3.3% with PCI and 3.4% with CABG.

The registry data collected on the nonrandomized patients who entered SYNTAX showed a similar pattern of results.

In 192 of the 198 patients who could be treated only by PCI and were followed for 1 year, the combined rate of death and MI was 10.5% and there were no strokes. In 644 patients who could be treated only by CABG and who were followed for 1 year, the combined rate of death, MI, and stroke was 6.6%, including a 2.2% rate of strokes. The repeat revascularization rates were 12.0% with PCI and 3.0% with CABG, producing a 0.9% quadruple end point rate of 20.4% with PCI and 8.8% with CABG, reported Dr. Mohr, a cardiovascular surgeon at the heart center of the University of Leipzig, Germany.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>CABG (n = 903)</th>
<th>PCI (n = 903)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>3.5%</td>
<td>4.3%</td>
</tr>
<tr>
<td>Nonfatal stroke</td>
<td>2.2%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Nonfatal myocardial infarction</td>
<td>3.2%</td>
<td>4.8%</td>
</tr>
<tr>
<td>Combined rate of death, stroke, and MI</td>
<td>7.7%</td>
<td>7.6%</td>
</tr>
<tr>
<td>Repeat revascularization</td>
<td>5.9%</td>
<td>13.7%</td>
</tr>
<tr>
<td>Combined rate of death, stroke, MI, and repeat revascularization</td>
<td>12.1%</td>
<td>17.8%</td>
</tr>
</tbody>
</table>

*Statistically significant difference between groups. Source: Dr. Serruys